Dropping health plan for Obamacare, this firm saved money but sacrificed choice
RANAC Corp., a small firm in Indianapolis, cut its spending on health benefits 25 percent after dropping its group health plan. Could it be a sign of things to come?
Life Science & Biotech
Articles
Drugmaker hid diabetes drug’s cancer risks, lawyer says
Takeda Pharmaceutical Co. executives covered up the cancer risks of its diabetes medicine Actos to protect billions of dollars in sales, a lawyer for two women argued.
Pence’s HIP 2.0 insurance expansion has national aspirations all over it
Gov. Pence's HIP 2.0 plan is nothing less than an attempt to roll back liberal policy on low-income health benefits as far as currently possible–and to get other states to follow suit. It might even be an opening bid for president.
Marathon talks yield good deal for hospitals in Pence’s HIP expansion
Fees on hospitals will generate the lion’s share of the funds for Gov. Mike Pence’s Healthy Indiana Plan expansion. But the benefits hospitals will receive will outweigh those costs.
Study: Hospital-doctor hook-ups swell prices
Now that Indianapolis-area hospitals employ large numbers of physicians, a new study suggests the integrated health systems will be able to charge higher prices to private health insurers.
Algaeon to take big step after landing $2.75M
An Indianapolis-based biotech company plans to use $2.75 million in new funding to begin commercial production of its algae-based nutritional supplements, the firm announced Monday.
U.S. House votes to revive expired research tax credit
The 274-131 vote follows calls to restore the credit by a coalition of companies including Indianapolis-based Eli Lilly and Co. and Texas Instruments Inc.
Indy’s most profitable hospitals, revisited
On the eve of Obamacare, almost no central Indiana hospitals were having trouble making money. Hip replacements, heart surgery and Hamilton County were the biggest drivers of profits.
Life sciences critical mass elusive in Indiana after years of effort
Attempts to build the sector are making headway, but Indiana still lags leading states.
Time to eat crow and fix my error on Obamacare sign-ups
When I predicted on March 13 that Obamacare would fail to expand individual private insurance coverage in Indiana, I was completely off. It now looks like an extra 30,000 Hoosiers have bought individual health insurance this year.
A silver lining for Endocyte
The news this morning couldn’t have been worse for Endocyte Inc. But if it had to come, the timing couldn’t have been better–because it allowed Endocyte to raise a pile of cash to spend on the other drugs in its pipeline.
Endocyte shares plunge 60 percent after drug trial is stopped
Endocyte Inc.’s stock fell more than 60 percent in early trading Friday after the drug it’s developing with Merck & Co.’s backing failed to help patients in a trial for ovarian cancer.
IU plots $200M life sciences hub in former Wishard Hospital
The envisioned 26-acre, $200-million-or-more complex would bridge IU’s School of Medicine with the city’s life sciences firms, including those at the nascent 16 Tech, a business park.
Enough blame to go around
A new report from the Commonwealth Fund provides plenty to criticize everyone involved in health care in Indiana: It shows health care costs run higher in Indiana than the rest of the country while patients’ health and the quality of health care providers in some key areas are worse.
What health care really needs is a full-meal deal
Until doctors and hospitals make a whole lot more headway—or, perhaps, more accurately, are allowed to make more headway—in offering package deals, it’s hard to see major progress on containing out-of-control health care costs.
Life Sciences Power Breakfast transcript
Indianapolis Business Journal gathered leaders in Indiana’s life sciences industry for a Power Breakfast panel discussion April 24. Among other topics, the panelists discussed whether Obamacare helps or hurts companies in the industry, the biggest barrier to life sciences startups, and how rising activity among angel investors has changed the life sciences landscape.
Think Obamacare will help hospitals? Think again
The typical hospital around the country will see its profits wiped out entirely by the changes coming from health reform and the aging of the population. But in Indianapolis, the hits will be cushioned by this region's fatter commercial reimbursements.
Zimmer shares hit 13-year high on Biomet deal
The deal will help Zimmer, a maker of artificial hips and knees, take on Johnson & Johnson, the No. 1 manufacturer in the now-growing $45 billion market.
Dow AgroSciences reports record quarterly results
The Indianapolis-based subsidiary of the country’s largest chemical maker achieved all-time highs in revenue and earnings in the first quarter.
Blockbuster deal: Eli Lilly paying $5.4B for Novartis Animal Health
Eli Lilly and Co. has agreed to pay $5.4 billion for Novartis Animal Health in the second-largest deal in the company's history. The acquisition is part of a blockbuster three-way drug deal.